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Abstract
Background: Glioblastomas (GBMs) are highly malignant brain tumours with a poor prognosis, and current
cytotoxic regimens provide only a limited survival benefit. The PI3K/Akt/mTOR pathway has been an attractive
target for therapy due to its high activation in GBMs as well as other cancers. The dual pan-PI3K/mTOR kinase
inhibitor dactolisib (NVP-BEZ235) is an anti-neoplastic compound currently under investigation. However, little
is known about its efficacy in human GBMs. We aimed at evaluating the efficacy of dactolisib in human
glioblastoma cells, as well as in murine models carrying human GBM xenografts.
Methods: To assess the effect of dactolisib in vitro, MTS assay, manual cell count, BrdU incorporation and Annexin V
staining experiments were used to observe growth and apoptosis. Furthermore, Akt phosphorylation (S473), a
downstream target of PI3K, was explored by western blotting. Animal studies utilizing orthotopic xenograft models of
glioblastoma were performed in nude rats and NOD/SCID mice to monitor survival benefit or inhibition of tumor growth.
Results: We found that dactolisib in vitro shows excellent dose dependent anti-growth properties and
increase in apoptosis. Moreover, dose dependent inhibition of Akt phosphorylation (S473), a downstream
effect of PI3K, was observed by western blotting. However, in two independent animal studies utilizing nude
rats and NOD/SCID mice in orthotopic xenograft models of glioblastoma, we observed no survival benefit or
inhibition of tumour growth. Severe side effects were observed, such as elevated levels of blood glucose and
the liver enzyme alanine transaminase (ALT), in addition to diarrhoea, hair loss (alopecia), skin rash and
accumulation of saliva in the oral cavity.
Conclusion: Taken together, our results suggest that despite the anti-neoplastic efficacy of dactolisib in
glioma treatment in vitro, its utility in vivo is questionable due to toxicity.
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Background
Gliblastoma (GBM) is a highly infiltrative and aggressive
brain tumour for which no curative treatment exists. Not-
ably, median survival is approximately 14.6 months post
diagnosis, even when patients undergo multimodal treat-
ment combining surgery, radio- and chemotherapy [1].
Thus, the dismal prognosis for GBM patients urgently
calls for new therapeutic strategies. In recent years,
advances in delineating the molecular mechanisms
regulating tumour biology have laid the foundation for the
development of targeted drugs [2]. Typically, these com-
pounds are directed against the signalling pathways pro-
moting proliferation and survival [3–5]. A major challenge
however, is that the activated signalling pathways in
tumour cells show a considerable overlap with those of
healthy somatic cells [6]. Therefore, these drugs may cause
side effects and toxicity. For the same reason, new agents
need to undergo careful validation, regarding both their
anti-tumour properties, as well as their toxicities.
The PI3K/Akt/mTOR pathway is frequently deregulated
in GBM [7], and therefore represents an attractive target
for molecular therapies. Unfortunately, clinical trials of
tyrosine kinase inhibitors (TKIs) in glioblastoma have,
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despite good tolerability, generally showed limited efficacy
[8]. This may be due to several factors, such as genetic in-
stability and escape mechanisms, as well as inefficient
drug delivery and effects, pharmacokinetic properties and
unacceptable side effects [8]. Glioblastoma is character-
ized by heterogeneity, with a redundancy of activated sig-
nalling pathways without a unifying single dominant
oncogenic “driver” mutation [2]. Therefore, aiming at a
single target in GBM is unlikely to succeed [9]. As such,
dual inhibitors targeting several pathways may be an at-
tractive alternative. On the other hand, combination ther-
apy with several inhibitors is associated with increased
risk of dose limiting toxicity due to drug interactions and
risk of accumulated toxicity [10].
Due to structural similarities between the ATP-binding
domain of the p110 subunit of PI3K and the catalytic do-
main of mTOR, a class of dual inhibitors of pan-PI3K and
mTOR has emerged [11]. The dual pan-PI3K/mTOR kin-
ase inhibitor dactolisib, also known as NVP-BEZ235, is a
new drug within this class with potential anti-neoplastic
efficacy. Currently it is under investigation for several
cancers [12].
The aim of the present study was to validate dactoli-
sib as a glioblastoma therapy in vitro and in vivo, util-
izing glioma cells and clinically relevant animal models
of nude rats and NOD/ SCID mice carrying intracra-




The U87 (American Type Culture Collection, Rockville,
MD, USA, ATCC HTB-14) human glioblastoma cell line
was maintained in DMEM medium supplemented with
10 % fetal bovine serum, 3.2 % non-essential amino acids,
100 units/ml Penicillin/Streptomycin, 400 mol/l L-glutam-
ine (all Sigma-Aldrich, St.Lous, MO, USA) and 0.005 mg/
ml Plasmocin (InvivoGen, San Diego, CA, USA), at 37 °C
and 5 % CO2.
Cells from serially passaged xenograft spheroids (P3)
were maintained as a monolayer in NB medium (Thermo
Fisher Scientific Corporation, Carlsbad, CA, USA) with the
addition of 32 IE/ml heparin, 20 ng/ml bFGF and 20 ng/ml
EGF (Millipore Corporation, Billerica, MA, USA).
For in vitro assessment of dactolisib efficacy, a 10 mM
stock solution was prepared by dissolving dactolisib
(kindly provided by Novartis (Basel, Switzerland): Also,
dactolisib was obtained from Selleckchem (Houston, TX,
USA) in 100 % DMSO (Sigma Aldrich, St. Louis, MO,
USA). Further dilution was done in cell culture medium.
Patient tumour material
In our study, we used a GBM xenograft model (P3) pre-
viously described [13]. This model reflects the growth
pattern of human tumours in situ, including extensive
infiltration into the brain parenchyma, prominent angio-
genesis, and necrosis. In short, tumour biopsy tissue was
obtained from the operating theatre, Haukeland Univer-
sity Hospital, Bergen, after approval from the regional
Ethical Board and consent from patient. Tumour mater-
ial was then cut into smaller pieces and maintained in
medium to make spheroids [14], which again were seri-
ally passaged in rodents as described by Wang and col-
leagues [13]. In our experiment, the spheroids were
enzymatically dissociated at 37 °C by trypsin-EDTA
(Sigma-Aldrich, St. Louis, MO, USA) and DNase (Roche,
Basel, Switzerland) for implantation in rats. The cells
were resuspended in sterile PBS with 25 mM glucose
(both Sigma Aldrich, St. Louis, MO, USA) and kept on
ice until implantation of 100 000 cells in each animal.
Three spheroids ranging in size between 500 and
600 μm in diameter were used for implantation in each
mouse. The spheroids were kept in sterile, ice cold PBS
with 25 mM glucose until implantation.
Cell viability (MTS assay)
1000 U87 cells or 5000 P3 xenograft cells were seeded in
96-well plates 24 h prior to dactolisib exposure at fol-
lowing concentrations: 0, 1, 10, 20, 30, 40, 50 and 250
nM. After 72 h, the cells were analyzed using the MTS
viability assay according to the manufacturer’s protocol
(CellTiter 96® AQueous One Solution Cell Proliferation
Assay, Promega, Madison, WI, USA), and absorption
was measured at 490 nm using a plate reader (Asys
UVM340, Biochrom, Cambridge, UK). Viability was de-
termined relative to untreated controls. These data were
used to make dose response curves for determination of
IC50 values in GraphPad 6 Prism (GraphPad Software
Inc., La Jolla, CA, USA).
BrdU-pulsing
Cells exposed to 0, 10, 50, 250 and 1000 nM dactolisib
for 72 h, were treated with 10 μM BrdU (Sigma-Aldrich,
St. Louis, MO, USA) in medium for 45 min at 37 °C.
They were detached using a cell scraper, washed once
with 1xPBS and resuspended to a concentration of 1 ×
105 cells/ml. Cell suspensions were kept on ice and proc-
essed within minutes. One hundred microliter cell sus-
pension from each sample was loaded into individual
sample chambers and centrifuged in a Shandon CytoS-
pin centrifuge (Thermo Fisher Scientific, Wilmington,
DE, US) at 800 rpm for 3 min. Immobilized cells were
fixed (described in the ICC-section below), and subse-
quently subjected to immunocytochemistry, imaging and
quantification. For each slide, three randomly picked
areas (832 μm × 665.6 μm, 554 mm2) were selected for
quantification. The FITC stained cells and the total
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number of cells was manually counted, and the propor-
tion of FITC positive cells was calculated.
Immunocytochemistry (ICC)
Cells on coverslips in 24-well plates were fixed in 4 %
paraformaldehyde (Thermo Fisher Scientific Corpor-
ation, Carlsbad, CA, USA) for 10 min, permeabilized by
0.5 % Triton X-100 (Sigma-Aldrich, St. Louis, MO,
USA) in PBS for 4 min and incubated with blocking buf-
fer (0.5 % BSA (Sigma-Aldrich, St. Louis, MO, USA) in
PBS) for 15 min. All steps were performed at room
temperature. Cells were incubated with primary anti-
bodies overnight at 4 °C, in a humid atmosphere. The
primary antibodies used were total Akt, pAkt S473, pAkt
T308 (All Cell Signaling Technology, Danvers, MA,
USA), and BrdU (Abcam, Cambridge, UK) together with
DNAse (Roche, Basel, Switzerland). Following incuba-
tion, cells were washed in PBS and incubated with sec-
ondary antibodies for 45 min at 37 °C in a humid
atmosphere. The secondary antibodies used were FITC-
conjugated goat anti-mouse IgG1 and FITC-conjugated
goat anti-rabbit (both from Southern Biotechnologies
Associates Inc., Birmingham, AL, USA). After sequential
washing with PBS and deionized water, cells were
mounted with Vectashield mounting medium with DAPI
(Vector Laboratories, Burlingame, CA, USA). Fluores-
cent images were obtained with a Nikon TE2000-E
microscope (Nikon Corporation, Tokyo, Japan).
Cell number quantitation
Cells were seeded in 96-well plates 24 h prior to expos-
ure to dactolisib for 72 h at the following concentrations:
0, 10, 50 and 250 nM. The cells were detached enzymat-
ically by Trypsin-EDTA solution, transferred to a Burker
chamber haemocytometer and manually counted using a
light microscope.
Immunoblotting (Western blot)
Cell lysates were prepared by resuspending mechanically
harvested cells or finely minced tissue in kinexus buffer
(20 mM MOPS, 5 mM EDTA, 2 mM EGTA, protease- and
phosphatase inhibitor tablets (Roche, Basel, Switzerland)),
followed by Vibra-Cell sonication (Sonics & Materials Inc,
Newton, CT, USA) for 3 × 5 s. Protein concentrations were
determined using a Pierce BCA Protein Assay Kit (Thermo
Fisher Scientific Corporation, Carlsbad, CA, USA). 20 μg
lysate was mixed with NuPAGE LDS sample loading buffer
and NuPAGE sample reducing agent (both Thermo Fisher
Scientific Corporation, Carlsbad, CA, USA) and incubated
at 70 °C for 10 min. Samples were run on a pre-cast SDS-
gel (NuPage, Invitrogen, Thermo Fisher Scientific Corpor-
ation, Carlsbad, CA, USA) at 200 V for 60 min. Transfer to
a nitrocellulose membrane was done at 30 V for 80 min.
Following blocking in 5 % (w/w) Difco Skim milk powder
(Becton, Dickinson and Company, Franklin Lakes, NJ,
USA), in TBST (50 mM Tris, 150 mM NaCl, 0.05 %
Tween20) for 1 h at room temperature, the membrane was
incubated with primary antibody (total Akt, pAkt S473,
pAkt T308 (All Cell Signaling Technology, Danvers, MA,
USA) and β-actin (Santa Cruz Biotechnology Inc, Dallas,
TX, USA) or GAPDH (Abcam, Cambridge, UK) at 4 °C O/
N. The membrane was washed with TBST before incuba-
tion with the secondary antibodies goat anti-mouse IgG-
HRP (Santa Cruz Biotechnology Inc, Dallas, TX, USA) and
goat anti-Rabbit IgG (H+ L) Cross Adsorbed Secondary
Antibody, HRP conjugate (Thermo Fisher Scientific Cor-
poration, Carlsbad, CA, USA) for 1.5 h. For detection, the
Supersignal West Femto Maximum Sensitivity Substrate
(Pierce Biotechnology, Rockford, IL, USA) was used, and
chemiluminescent detection was obtained by a Fuji LAS
3000 Imager (Fuji Photo Film, Tokyo, Japan). Densitometric
quantification of the bands was done using ImageJ software
(National Institutes of Health, Bethesda, MA, USA).
Annexin V / Propidium Iodide (PI) apoptosis assay
Cells were stained with the Annexin V apoptosis assay ac-
cording to the manufacturer’s protocol (Thermo Fisher
Scientific Corporation, Carlsbad, CA, USA). Briefly, cells
were detached and washed twice by PBS (without calcium
and magnesium) and once in Annexin V binding buffer.
Samples were resuspended in 100 μl Annexin V binding
buffer and 5 μl Annexin V Alexa Fluor 488 and 1 μl PI
was added before incubation in the dark for 15 min at RT.
Four hundred microliter Annexin V binding buffer was
then added to each sample and the samples were kept on
ice and analysed immediately on the Accuri C6 (BD Bio-
sciences) flow cytometer.
Animals
The in vivo studies were performed on a total number of
33 athymic homozygous nude rats (Han: nru/nru Rowett)
and 32 NOD/SCID mice (NOD.CB17-PrkdcScid). Animals
were bred and maintained in animal facility at University
of Bergen, certified by AAALAC international. The ani-
mals were provided a standard pellet diet and tap water ad
libitum. They were kept in a pathogen free environment
at a constant temperature and humidity and standard 12/
12 h light and dark cycle.
Prior to tumour implantation, all animals were anaesthe-
tized with isoflurane gas (Abbott Laboratories, Abbot Park,
IL, USA) (3 % mixed with 50 % air and 50 % O2) and given
Marcaine (AstraZeneca, London, England) subcutaneously.
The head was secured in a stereotactic frame (Benchmark,
Neurolab, St Louis, MO, USA) before a longitudinal inci-
sion was made in the scalp. Through a burr-hole obtained
with a micro-drill, the tumour material was slowly inserted
via a Hamilton syringe with an inner diameter of 810 μm,
at the following coordinates for rats: 1 mm posterior of the
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bregma suture, 2 mm right of the sagittal suture and 3 mm
below the brain surface. For mice, the coordinates were
0.5 mm posterior of the bregma suture, 1.5 mm right of
the sagittal suture and 1.5 mm below the brain surface.
The skin incision was closed using an Ethilon 3-0 suture.
Animals were weighed five times a week on a PGW 2502e
weight (Adam Equipment, Danbury CT, USA), inspected
daily and euthanized by CO2 inhalation at the onset of
symptoms such as passiveness, neurological deficits or
other signs of illness. The brains were harvested, snap fro-
zen in liquid nitrogen and stored at −80 °C. All procedures
and experiments involving animals in this study were ap-
proved by The Norwegian Animal Research Authority
(Bergen, Norway) and is in accordance with Guide for the
Care and Use of Laboratory Animals (Institute for
Laboratory Animal Research, National Research Council.
Washington, DC: National Academy Press, 1996).
Animal medication
Tumour bearing animals were randomly assigned to two
different groups: 1) untreated controls and 2) dactolisib
treatment. The medication started by the time tumour en-
graftment was confirmed by MRI. Dactolisib was adminis-
tered by oral gavage, using malleable oral dosing needles
with silicone tips (Scanbur, Karlslunde, Denmark). Dacto-
lisib was delivered as a suspension in 0.5 % methyl cellu-
lose and 0.5 % Tween20 (both Sigma Aldrich, St. Louis,
MO, USA), once daily, 5 days a week. Vehicle (0.5 % me-
thyl cellulose and 0.5 % Tween 20) was equally given per
os(p.o.) to the animals in the control group. Both groups
received 10 ml/kg solution each treatment day.
After longitudinal observation of healthy, non-implanted
animals, the dose was set to 10 mg/kg for rats. The dose
45 mg/kg for mice was determined from studies published
by other groups [15, 16], but was rapidly adjusted to
25 mg/kg in the study of tumour bearing mice.
During the dactolisib-exposure of non-tumour bearing
animals, dactolisib was delivered as a solution in 1 vol-
ume NMP and 9 volumes PEG300 (Both Sigma Aldrich,
St. Louis, MO, USA).
Assessment of side effects
During the daily inspection of the animals, any changes
and possible side effects observed (gavage reluctance, skin
rash, diarrhoea and excessive salivation) were registered.
To allow for semi-quantitative comparison between the
groups, the animals were scored for the presence of side
effects. The total number of events for each possible side
effect was summed and displayed as a histogram.
Blood collection and analysis
Immediately post mortem, blood was collected from the
aorta. The blood was transferred to an Eppendorf tube,
allowed to coagulate at room temperature for 30 min
and centrifuged for 10 min at room temperature, 1300
rcf. The plasma was then collected and stored at −80 °C
until analysis by Sentrallaboratoriet NMBU Veteri-
nærhøgskolen (Oslo, Norway). Blood glucose levels were
measured by Accu-Chek Aviva blood glucose meter
(Roche, Basel, Switzerland) by one drop of freshly col-
lected blood.
Magnetic resonance imaging (MRI)
The animals were anaesthetized with 3 % isoflurane, in a
mixture of 50 % N2O and 50 % O2, and brain images were
obtained, using a Bruker Pharmascan 7 T MR scanner
(Bruker Biospin MRI GmbH, Ettlingen, Germany). For rats,
a coronal T2 weighted TurboRARE sequence was acquired
(TR 3500 ms and TE 36 ms), in addition to an axial T1
weighted RARE sequence (TR 1000 ms and TE 9 ms), after
subcutaneous injection of contrast agent (1–2 ml of
Dotarem, 279.3 mg/ml, Guerbet LLC, Bloomington IN,
USA). Common for both sequences for rats was slice thick-
ness 1 mm, FOV 3.2 cm, matrix size 256 × 256, 20 slices.
Similarly, for mice, a coronal T2 weighted TurboRARE
sequence was acquired (TR 4300 ms and TE 36 ms), in
addition to a coronal T1 weighted RARE sequence (TR
1000 ms and TE 9 ms), after subcutaneous injection of
contrast agent (0.2 ml of Dotarem). Common for both
sequences for mice was slice thickness 1 mm, FOV
2 cm, matrix size 256 × 256 and 15 slices. The tumour
volumes at treatment start and on follow-up MRI were
calculated in Gamma Plan (Elekta Instrument AB,
Stockholm, Sweden).
Statistical analysis
In vitro experiments were repeated three times and
assessed by ANOVA with Tukey’s multiple comparion
test, with a p-value <0.05 considered significant. Kaplan-
Meier survival curves were generated in GraphPad Prism
6 (GraphPad Software Inc., La Jolla, CA, USA). Median
survival times for the treatment groups were compared
using the log-rank test.
Results
Dactolisib inhibits cell proliferation and induces apoptosis
of glioblastoma cells in vitro
The cytotoxicity of dactolisib on glioblastoma cells
was assessed by treating the cell line U87 and mono-
layers established from the P3 GBM xenografts to
various concentrations of dactolisib. Using the MTS
viability assay, dose response curves were generated
and IC50 values were calculated thereof (Fig. 1a).
IC50 was established at 15.8 nM and 12.7 nM for
U87 and P3 glioma cells, respectively. To rule out the
possible effect of altered cell metabolism on MTS
assay, we verified the cell number by manual count-
ing (Fig. 1b). This showed that dactolisib reduced the
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Fig. 1 a IC50 doses of dactolisib for P3 (left) and U87 (right) glioma cells, generated from MTS assay. b Relative cell number of P3 (left) and U87
(right) glioma cells exposed to dactolisib at doses indicated for 72 h. c Quantification of BrdU positive P3 (left) and U87 (right) glioma cells treated
with dactolisib at doses indicated for 72 h and subsequently pulsed with BrdU. d Quantification of Annexin V- and PI-positive P3 (left) and U87
(right) glioma cells treated with dactolisib at doses indicated for 72 h and subsequently incubated with PI and Annexin V Alexa Fluor 488 conjugate.
Error bars represent s.d. of three independent experiments. *P <0.05, **P < 0.01, ***P < 0,001, ****P < 0,0001
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number of cells significantly in a dose dependent
manner. Since a relative reduction in cell number
may reflect either increased cell death, or reduced
proliferation, we quantified both the proliferation and
apoptotic rates of dactolisib-treated cells. For prolifer-
ation assessment, cells were pulsed with BrdU after
dactolisib exposure, and the subsequent quantification
of BrdU positive cells demonstrated a clear dose
dependent reduction in cell proliferation (Fig. 1c).
Annexin-PI Apoptosis assay post dactolisib-exposure
showed a dose-dependent increase of apoptosis
(Fig. 1d). In summary, these results indicate that dac-
tolisib is an effective inhibitor of glioblastoma cell
proliferation and overall growth, as well as an inducer
of apoptosis in vitro. The solvent (DMSO) did not
show anti-proliferative effect on glioblastoma cells in
equivalent doses alone (data not shown).
Dactolisib inhibits phosphorylation of Akt in vitro
To further assess dactolisib’s inhibitory effect on PI3K,
we evaluated the influence on Akt, a central downstream
effector of PI3K. Akt is activated by phosphorylation of
the amino acid residues threonine 308 (T308) and of
serine 473 (S473). We performed ICC of U87 cells on
coverslips exposed to various concentrations of dactoli-
sib, suggesting a dose dependent reduction of Akt phos-
phorylation (Fig. 2a). For a quantitative analysis, we
further performed western blot analysis of lysates from
U87 (Fig. 2b) and P3 (Fig. 2c) cells exposed to dactolisib
in various concentrations and assessed band intensity by
densitometric analysis. A dose dependent reduction of
Akt phosphorylation at S473 was observed, whereas the
degree of Akt phosphorylation at T308 was unchanged.
No reduction of the total levels of Akt was observed, in-
dicating that the reduced level of phosphorylated Akt
was caused by an inhibition of its phosphorylation and
not by a decrease of the Akt protein level.
Dactolisib causes adverse effects in healthy nude rats
To assess tolerability and determine the maximum toler-
ated dose of dactolisib in vivo, healthy nude rats were
exposed to dactolisib at doses of 10 and 20 mg/kg. After
1 week, pronounced hair loss (alopecia) was observed in
all exposed rats (Fig. 3a).
The following side effects were found to appear in a
dose dependent manner: Maculopapular rash (Fig. 3b and
e), hyperglycemia (Fig. 3c), elevated alanine transaminase
(ALT) activity in serum (Fig. 3d), and diarrhoea (Fig. 3e).
Reluctance to gavage was observed in a dose dependent
manner (Fig. 3e). Excess saliva in the oral cavity was ob-
served in both treatment groups, in a dose dependent
manner (Fig. 3e). Due to possible irritation of mucosae by
the solvent (NMP/PEG), we also assessed the effects of
the inert compound methyl cellulose as delivery vehicle.
We found that the effects were less pronounced, yet still
observed in a dose dependent manner when dactolisib
was administered with methyl cellulose (data not shown).
We thus chose to conduct the remaining studies with me-
thyl cellulose as delivery vehicle.
Based on the unacceptable weight loss for rats under
dactolisib dose escalation from 10 mg/kg to 20 mg/kg
(Fig. 3f ), we determined 10 mg/kg to be maximal toler-
ated dose (MTD) and hence this dose was applied for
the study of a potential anti-proliferative effect on glio-
blastoma cells in vivo.
Dactolisib does not inhibit tumour growth or prolong
survival for rats carrying orthotopic GBM xenografts
The anti-tumour efficacy of dactolisib was evaluated in a
clinically relevant patient-based GBM model. In vivo
propagated P3 GBM xenografts were intracranially im-
planted in nude rats. This model reflects the growth
pattern of human tumours in situ, including extensive in-
filtration into the brain parenchyma, prominent angiogen-
esis, and necrosis [13]. Three weeks after tumour
implantation, magnetic resonance imaging (MRI) con-
firmed tumour engraftment in all rats, and the animals
were randomly assigned to two treatment groups: one re-
ceiving dactolisib, and one receiving vehicle only (control).
Dactolisib did not increase the survival of treated animals
(Fig. 4a). Although not statistically significant (p = 0.0845),
the animals in the treatment group showed a tendency to-
wards shorter survival than the rats in the control group.
MRI performed after 1 and 2 weeks of treatment showed
tumours of comparable size in both groups (Fig. 4b).
Healthy NOD/SCID mice tolerate higher doses of
dactolisib than healthy nude rats
The failure to show dactolisib efficacy in glioblastoma
bearing nude rats, together with its excellent in vitro
anti-tumour effect, suggested that 10 mg/kg dactolisib
was not enough to reach a therapeutic concentration
within the brain. Since our preceding experiments indi-
cated that a higher dose was unacceptable for rats, we
next investigated the effect of dactolisib on mice.
Healthy, non-implanted NOD/SCID mice were adminis-
tered dactolisib at doses of 45 and 25 mg/kg by oral gav-
age. Mice receiving 25 mg/kg dactolisib had no weight
loss compared to the control group, while the group ex-
posed to 45 mg/kg dactolisib lost weight during the
treatment (Fig. 5a). However, the weight loss was within
less than 15 %, and the animals normalized their weight
after the 2-day rest in each treatment cycle.
45 mg/kg dactolisib is highly toxic for mice carrying
intracranial GBM xenografts
In vivo passaged patient-derived GBM xenografts
were intracranially implanted in NOD/SCID mice.
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Three weeks after implantation, magnetic resonance
imaging (MRI) confirmed tumour engraftment in all
mice, and the animals were randomly assigned to two
groups: one receiving 45 mg/kg dactolisib, and one
receiving vehicle only (control). However, within the
first week of treatment, all mice in the treatment
group died, while all animals in the control group
survived (Fig. 5b).
Fig. 2 a Immunocytochemistry showing Akt phosphorylation in U87 cells after exposure to dactolisib at doses indicated for 72 h. Upper panel: Akt
phosphorylated at site T308 (FITC, green). Middle panel: Akt phosphorylated at site S473 (FITC, green). Lower panel: Total Akt-levels (FITC, green). Nuclear
counterstaining: DAPI (blue). b Left: Western blots showing levels of pAkt (T308), pAkt (S473) andtotal Akt in U87 cells exposed to dactolisib at doses
indicated for 72 h. Right: Densitometric assessment of western blot, showing relative change in phosphorylation. c Left: Western blot showing levels of
pAkt (T308), pAkt (S473) and total Akt in P3 cells exposed to dactolisib at doses indicated for 72 h. Right: Densitometric assessment of western blot,
showing relative change in phosphorylation. Error bars represent s.d. of Error bars represent s.d. of three (a and b) and two (c) independent
experiments. *P <0.05, **P < 0.01, ***P < 0,001
Netland et al. BMC Cancer  (2016) 16:657 Page 7 of 12
25 mg/kg dactolisib does not improve survival for mice
carrying intracranial GBM xenograft, and does not reduce
tumour growth
After the death of all mice receiving 45 mg/kg dacto-
lisib, half of the mice in the control group were then
allocated to a new treatment group receiving 25 mg/
kg dactolisib. No survival benefit was observed in the
animals treated with 25 mg/kg dactolisib (Fig. 5b).
MRI 1 week after initiation of the treatment with
25 mg/kg dactolisib revealed a slightly smaller, yet
not statistically significant, tumour in the treatment
group (Fig. 5c).
Discussion
In the present study, we have demonstrated the in vitro
efficacy of the dual PI3K/mTOR inhibitor dactolisib,
with dose dependent reduction of glioblastoma cell pro-
liferation, increased apoptosis and corresponding reduc-
tion of Akt phosphorylation.
Fig. 3 a Coat of nude rats before (left panel) and after (right panel) 1 week of treatment. One rat from the dactolisib treatment group (10 mg/kg)
is shown in the upper panel, while one rat from the control group (vehicle only) is shown in the lower panel. b Maculopapular rash observed in
some rats during dactolisib exposure. c Blood glucose levels in nude rats after 6 weeks of dactolisib treatment. *P <0.05. d Serum levels of ALT
from rats exposed to dactolisib for 6 weeks. *P <0.05. E) Graphic presentation of adverse effects observed in nude rats exposed to dactolisib. (n =
6 for each group) F) Weight development in nude rats during dactolisib exposure (n = 4). Red arrow indicates dose increase from 10 mg/kg
to 20 mg/kg
Fig. 4 a Kaplan-Meyer survival curve for nude rats carrying orthotopic GBM xenografts (P3) (p-value 0.0845). (n = 6 for control group, n = 5 for
dactolisib-group). b MRI-based assessment of all tumour volumes
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Our in vivo studies revealed that the most prominent
side effect of dactolisib treatment was hair loss (alope-
cia), which was regarded a sign of successful administra-
tion and absorption of the compound, since the cells
within the hair follicle have a high basal level of PI3K ac-
tivity [17], and its inhibition thus leads to hair loss.
Moreover, dose dependent hyperglycemia was also ob-
served. Given the well-described role of PI3K in insulin
signalling [18, 19], elevated blood glucose may be an in-
dispensable adverse effect of PI3K inhibition. Hypergly-
cemia is a particularly problematic side effect from a
compound for glioblastoma treatment, since many GBM
patients experience elevated blood glucose due to steroid
treatment. Furthermore, hyperglycemia is associated
with poorer survival for GBM patients [20]. An elevated
serum alanine transaminase (ALT) activity was also
Fig. 5 a Weight development in healthy, non-tumour bearing NOD/SCID mice during dactolisib exposure (n = 6 for each group). b Kaplan Meyer
survival curve for NOD/SCID mice carrying orthotopic GBM xenografts (P3). Left red arrow indicates treatment start of 45 mg/kg dactolisib (n = 7). Right
red arrow indicates splitting of control group (n = 7) into one treatment group (25 mg/kg) (n = 3) and one control group (n = 4). Red line shows survival
for mice in the treatment group of 45 mg/kg dactolisib, green line shows survival for mice in the treatment group of 25 mg/kg dactolisib, and black line
shows survival for mice in the control group (vehicle only). (P-value 0.1788 for 25 mg/kg vs control). c MRI-based assessments of all tumour volumes
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found in the rats exposed to dactolisib. ALT serves as a
biomarker of hepatotoxicity [21], and may thus indicate
hepatocellular damage as a result of dactolisib exposure.
Interestingly, elevated activities of serum ALT is com-
monly observed in diabetic patients [22]. After a few
days of accustoming, rats were cooperative during gav-
age. However, after 3 weeks they became increasingly re-
luctant to drug administration. This might represent
mucosal irritation, and was seen in the treatment groups
as well as in the control group, yet in a dose dependent
manner. Possibly, mechanical irritation by the oral dos-
ing, together with the possible chemical irritation by the
vehicle, might be the explanation for the observed mu-
cosal irritation in the control group. Nevertheless, the
dose dependent increase in mucosal irritation in the
treatment group was most likely caused by dactolisib.
Mucositis has also been reported as a side effect from
dactolisib in a phase I clinical trial [23]. Diarrhoea was
also observed across the groups, yet more often and
more severe in the group of animals treated with higher
the dose of dactolisib. Excess of mouth fluid, interpreted
as mucositis, was observed in a dose dependent manner.
Notably, all of the above described side effects have also
been observed with dactolisib in clinical trials [24].
Vomiting has also been reported from these trials. How-
ever, rats and mice lack the emetic reflex [25].
For animal experiments, Novartis, the manufacturer of
dactolisib, advices dactolisib administered as a suspension
in methyl cellulose or as a solution in NMP/PEG. The lat-
ter is more commonly used. Hence, for study of dactolisib
exposed, non-tumour bearing rats, we used NMP/PEG as
vehicle in both treatment groups, as well as in the control
group. However, in our experience, the viscosity of NMP/
PEG results in a more tedious procedure, and we thus ex-
amined the effects of dactolisib as a suspension in methyl
cellulose. Our findings indicate that NMP/PEG as vehicle
for dactolisib delivery causes adverse effects or exacerbates
the adverse effects of dactolisib, which are reduced if
NMP/PEG is replaced by methyl cellulose.
The in vivo studies were initially performed in nude
rats, as this was the animal species the GBM xenograft
model we used was first established in. The failure to
show efficacy of dactolisib against glioblastoma in nude
rats, together with the excellent in vitro anti-tumour ef-
fect, led us to hypothesize that MTD for nude rats,
10 mg/kg dactolisib, was not high enough to reach a
therapeutic concentration within the brain. We thus
next investigated the effect of dactolisib on healthy, non-
implanted NOD/SCID mice, and found that dosing up
to 45 mg/kg was tolerable, although side effects have
been found in mice treated with dactolisib for a pro-
longed period of time with intraperitoneal (i.p.) injec-
tions [26]. However, 45 mg/kg proved to be intolerable
in mice carrying intracranial xenografts. Within the first
week of treatment, all mice in the treatment group died,
while all animals in the control group survived. The pos-
sible explanation is that the burden of a test substance
causing adverse effects may be intolerable for the weak-
ened animal already carrying an intracranial tumour.
After the first treatment cycle, where all mice in the
treatment group died, half of the animals in the control
group were allocated to a new treatment group receiving
lower dose of 25 mg/kg dactolisib. No survival benefit
was observed with this dose and MRI 1 week after initi-
ation of the treatment at this dose level, revealed tu-
mours of comparable size in both groups. It is still
possible that dactolisib exerts anti-tumour efficacy but
that this is outweighed by its side effects. Thus, a change
of the route of administration may improve the results.
Since many of the side effects observed stem from the
gastrointestinal tract, it might be advisable to avoid oral
ingestion, or aim at reducing the irritation of the GI by
carefully designed medication, such as enterocapsules.
The dosage schedule is also of importance. Alcazar et al.
have reported the use of dactolisib doses up to 75 mg/kg
for nude mice, yet with medication every other day [27].
The tumour site may also influence the tolerance, as
Klinger et al. gave 45 mg/kg/day p.o. and Yu et al. ad-
ministered 25 mg/kg/day i.p. on mice with subcutaneous
glioma tumours [28, 29]. Other dosage schedules have
been used for other cancer types, although many use a
different route of administration and/or time of expos-
ure [30–36].
Alternatively, the lack of efficacy may also be due to lim-
ited distribution across the blood-brain-barrier (BBB). The
low molecular weight of dactolisib (469.5 Da) and its lipo-
philic capacity satisfy the basic requirements for crossing
the BBB [37], yet no documentation on crossing of BBB
by dactolisib has been found to date. However, two studies
report dactolisib efficacy on intracranial tumours in nude
mice, indicating crossing of the BBB [16, 27]. This is in
contrast to our present data, and the reason for this dis-
crepancy is not clear. However, whereas our data were ob-
tained in nude rats and NOD/SCID mice, nude mice were
applied for these studies.
Other types of cancer may benefit from dactolisib at
lower doses than those required for GBM. Of particular
interest is the study of Wang et al., which reports that
side effects during dactolisib-treatment of breast cancer
bearing mice are reduced by the addition of dihydrotes-
tosterone (DHT) [38]. The activation of androgen recep-
tor (AR) by DHT is beneficial for breast cancer patients.
However, AR signaling may aggravate gliomas [39], and
the safety of using DHT in GBM patients is uncertain.
Currently, there are no ongoing clinical studies for the
use of dactolisib in glioblastoma, yet there is one recruit-
ing phase I/II study (NCT01508104), which includes ad-
vanced solid cancers, also covering glioblastoma. The aim
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of this study is to assess the safety of combination treat-
ment with another mTOR inhibitor, everolimus.
Toxicity of therapeutic compounds in palliative cancer
therapy is an important issue. To date no curative treat-
ment option for glioma has been established. The stand-
ard therapy is associated with an acceptable side effect
profile. The evaluation of clinical benefit versus toxicity
is at the discretion of the oncologist. However, new
therapeutic compounds should be implemented into the
clinic with caution, and drugs with marginal, if any, effi-
cacy and considerable toxicity compromising the quality
of life should be avoided.
Conclusion
Taken together, our findings of dactolisib anti-tumour
efficacy in vitro support the concept of application of
dual inhibitors in cancer therapy. However, the demon-
strated association of a spectrum of side effects from
dactolisib treatment in two different murine brain
tumour models, suggest that further studies need to
proceed with caution.
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